FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer

NCT01358812 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colo-rectal Cancer

Interventions

DRUG: FOLFOXIRI + Panitumumab

Sponsor

Gruppo Oncologico del Nord-Ovest